Prothena Corporation plc
PRTA
Rank in Stocks
#12657
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses... Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual AΓ-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-AΓ antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Share Price
$8.78
Last synced: 2026-11-09
Market Cap
$450.48M
Change (1 day)
10.10%
Change (1 year)
-16.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prothena Corporation plc (PRTA)
Category
Healthcare
EPS for Prothena Corporation plc (PRTA)
EPS as of September 2026 TTM: $-0.47
According to Prothena Corporation plc's latest financial reports, its current EPS (TTM) is $-0.47. At the end of 2025 the company had an EPS of $-4.53, a decrease compared to its 2024 EPS of $-2.27.
EPS history for Prothena Corporation plc from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.47 | -89.62% |
| 2025 | $-4.53 | 99.56% |
| 2024 | $-2.27 | -17.75% |
| 2023 | $-2.76 | 11.74% |
| 2022 | $-2.47 | -263.58% |
| 2021 | $1.51 | -154.32% |
| 2020 | $-2.78 | 42.56% |
| 2019 | $-1.95 | -50.38% |
| 2018 | $-3.93 | -3.44% |
| 2017 | $-4.07 | -12.66% |
| 2016 | $-4.66 | 75.19% |
| 2015 | $-2.66 | 817.24% |
| 2014 | $-0.29 | -86.82% |
| 2013 | $-2.20 | -22.54% |
| 2012 | $-2.84 | 69.05% |
| 2011 | $-1.68 | 136.62% |
| 2010 | $-0.71 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,431.91% |
US
|
|
| $-7.07 | 1,404.26% |
US
|
|
| $-5.29 | 1,025.53% |
AU
|
|
| $12.88 | -2,840.45% |
BE
|
|
| $21.56 | -4,687.23% |
NL
|
Questions about Prothena Corporation plc's earnings per share (EPS)
What is Prothena Corporation plc's earnings per share (EPS)?
Prothena Corporation plc's earnings per share (EPS) over the last twelve months is $-0.47, as of Sep 2026.
What was Prothena Corporation plc's earnings per share (EPS) in 2025?
In 2025, Prothena Corporation plc's earnings per share (EPS) was $-4.53, compared with $-2.27 in 2024.
How has Prothena Corporation plc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Prothena Corporation plc's earnings per share (EPS) was highest in 2021 ($1.51) and lowest in 2025 ($-4.53).
How does Prothena Corporation plc's earnings per share (EPS) compare with similar companies?
Prothena Corporation plc's earnings per share (EPS) ($-0.47) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.